IMMUNITY TO S PNEUMONIAE VACCINE IN HIV-INFECTED AFRICAN-AMERICANS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。感染HIV的非裔美国成年人对肺炎链球菌荚膜多糖（血清型4,6b, 9V, 14, 18C， 19F和23F）的免疫水平较低。目前推荐的23价肺炎球菌多糖疫苗不能对侵袭性肺炎球菌疾病提供很好的保护。在感染hiv的非裔美国成年人中使用免疫原性更强的结合肺炎球菌七价疫苗的经验有限。我们的假设是，它们对肺炎球菌结合疫苗（CPV）的免疫应答比对肺炎球菌多糖疫苗（PPV）的免疫应答更高。特定的目标;1)测定4、6B、9V、14、18C、19F血清型抗体水平；2) opsonophagocytic assay （OPA）测定功能性抗体应答3)测定患者血清型特异性免疫与血培养分离的肺炎链球菌血清型的相关性4)测定抗体水平与免疫学和病毒学参数的相关性5)测定hiv感染成人对连续接种结合肺炎球菌产生的免疫七价疫苗（CPV）和23价肺炎球菌多糖疫苗（PPV）与单剂量肺炎球菌多糖疫苗的比较。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HIV infected African-American adults have low levels of immunity to Streptococcus pneumoniae capsular polysaccharide (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F). The currently recommended 23-valent pneumococcal polysaccharide vaccine does not offer very good protection against invasive pneumococcal disease. Experience with the more immunogenic conjugate pneumococcal heptavalent vaccine in HIV-infected African-American adults is limited. Our hypothesis is that they will have higher immune response to pneumococcal conjugate vaccine (CPV) than to pneumococcal polysaccharide vaccine (PPV). Specific Aims; 1) To determine antibody levels to serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F of Streptococcus pneumoniae capsular polysaccharide (PPS) in HIV-infected Blacks 2) To determine the functional antibody response by opsonophagocytic assay (OPA) 3) To determine the correlation between the patient serotype-specific immunity and S. pneumoniae serotype isolated from blood culture 4) To correlate antibody levels with immunologic and virologic parameters 5) To determine immunity generated in HIV-infected adults against sequential vaccination with conjugate pneumococcal heptavalent vaccine (CPV) and 23-valent pneumococcal polysaccharide vaccine (PPV) as compared with single-dose pneumococcal polysaccharide vaccine.